Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference
Rhea-AI Summary
Pacira BioSciences (NASDAQ:PCRX) will participate in an analyst-led fireside chat at the Barclays 28th Annual Global Healthcare Conference on March 11, 2026 at 2:30 PM ET in Miami. Live audio will stream on the company Events page and a replay will be available for two weeks.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – PCRX
On the day this news was published, PCRX gained 3.44%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 02 | Clinical data update | Positive | -2.9% | Real-world IGOR registry data presented for EXPAREL and iovera° knee treatments. |
| Feb 26 | Earnings results | Positive | -3.0% | Q4 and 2025 results with revenue growth, profitability and 2026 guidance disclosed. |
| Feb 12 | Earnings call date | Neutral | +1.5% | Announcement of timing and access details for 2025 results conference call. |
| Feb 12 | Policy/survey news | Positive | -1.3% | NOPAIN Act survey data highlighting increased non-opioid use and reduced opioid prescribing. |
| Feb 09 | Equity grants | Neutral | +0.3% | Inducement stock options and RSUs granted under Nasdaq Listing Rule 5635(c)(4). |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive or neutral news (clinical data, earnings, policy-related updates) has often been followed by flat-to-negative price reactions, showing several divergences between news tone and short-term moves.
Over the past month, Pacira has reported multiple developments. On Feb 26, it posted Q4 and full-year 2025 results with $726.4M revenue and a return to GAAP profitability, yet shares fell on that day. Earlier in February, it highlighted NOPAIN Act survey data and IGOR registry outcomes for EXPAREL and iovera°, both supportive of its non-opioid strategy. Inducement equity grants and the earnings-date announcement had modest market impact. Today’s Barclays fireside chat fits this pattern of frequent investor-facing communications.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the Barclays 28th Annual Global Healthcare Conference at 2:30 PM ET on Wednesday, March 11, 2026 in Miami. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.
Company Contact: Pacira BioSciences, Inc. Christian Pedetti (973) 254-4387 Christian.pedetti@pacira.com